^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

γδ TCR modulator

12d
DELTACEL-01: Safety Study for a Gamma Delta T Cell Product Used with Low Dose Radiotherapy in Patients with Locally Advanced or Metastatic NSCLC or Solid Tumors with Bone Metastases (clinicaltrials.gov)
P1, N=48, Recruiting, Kiromic BioPharma Inc. | Trial completion date: Jan 2027 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Oct 2025
Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
18d
SGNEGFRd2-001: A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=275, Recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Sep 2028 --> Jul 2029 | Trial primary completion date: Jul 2027 --> Jul 2028
Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
|
EGFR mutation • MSI-H/dMMR • ALK rearrangement
|
PF-08046052
24d
New P1/2 trial
|
cyclophosphamide • fludarabine IV
26d
Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL (clinicaltrials.gov)
P1/2, N=30, Recruiting, Chinese PLA General Hospital | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
|
CD19 positive • Chr t(11;14)
|
cyclophosphamide • fludarabine IV
29d
New P1/2 trial
29d
Enrollment open • Trial initiation date
|
IL3RA (Interleukin 3 Receptor Subunit Alpha)
2ms
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML (clinicaltrials.gov)
P1, N=16, Terminated, Lava Therapeutics | Phase classification: P1/2 --> P1 | N=102 --> 16 | Active, not recruiting --> Terminated; The decision to discontinue LAVA-051clinical trial follows a recent review of the competitive landscape that has continued to evolve (Business decision). The decision is not due to safety concerns.
Phase classification • Enrollment change • Trial termination
|
LAVA-051
2ms
Enrollment closed
|
Keytruda (pembrolizumab)
2ms
A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus (clinicaltrials.gov)
P1/2, N=15, Recruiting, Wuhan Union Hospital, China | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2025
Trial completion date • Trial primary completion date
3ms
Enrollment open • Metastases
|
IL2 (Interleukin 2)
|
Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • ACE2016
3ms
CAR001: A Safety and Efficacy Study of Allogeneic CAR Gamma-Delta T Cells in Subjects with Relapsed/Refractory Solid Tumors (clinicaltrials.gov)
P1/2, N=60, Recruiting, Ever Supreme Bio Technology Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
4ms
Allogeneic NKG2DL-targeting CAR γδ T Cells (CTM-N2D) in Advanced Cancers (ANGELICA) (clinicaltrials.gov)
P1, N=12, Recruiting, CytoMed Therapeutics Pte Ltd | Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Dec 2026 | Trial primary completion date: Mar 2023 --> Nov 2025
Enrollment open • Trial completion date • Trial primary completion date • Metastases
|
NKG2D (killer cell lectin like receptor K1)
|
CTM-N2D
5ms
Clinical Study on the Treatment of Malignant Brain Glioma by QH104 Cell Injection (clinicaltrials.gov)
P1/2, N=25, Suspended, Dushu Lake Hospital Affiliated to Soochow University | Recruiting --> Suspended
Trial suspension
|
CD276 (CD276 Molecule)
|
CD276 expression
|
QH104
5ms
Enrollment closed • Enrollment change
|
IDH wild-type
|
temozolomide
5ms
New P1 trial
|
IL3RA (Interleukin 3 Receptor Subunit Alpha)
|
CD123 positive • IL3RA positive
6ms
Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT (clinicaltrials.gov)
P1, N=20, Active, not recruiting, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Active, not recruiting | N=32 --> 20 | Trial completion date: Jun 2025 --> Sep 2026 | Trial primary completion date: Jun 2025 --> Sep 2025
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
7ms
A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma (clinicaltrials.gov)
P1, N=30, Recruiting, Cullinan Therapeutics Inc. | Not yet recruiting --> Recruiting
Enrollment open
|
CLN-619
8ms
SUPLEXA-101: Study of SUPLEXA in Patients With Metastatic Solid Tumours and Haematologic Malignancies (clinicaltrials.gov)
P1, N=35, Completed, Alloplex Biotherapeutics Inc | Active, not recruiting --> Completed | N=60 --> 35 | Trial completion date: Feb 2025 --> Jul 2024 | Trial primary completion date: Feb 2024 --> Jul 2024
Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Metastases
8ms
EVICTION: First-in-Human Study of ICT01 in Patients With Advanced Cancer (clinicaltrials.gov)
P1/2, N=150, Recruiting, ImCheck Therapeutics | Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Mar 2024 --> Jun 2025
Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • Metastases
|
Keytruda (pembrolizumab) • ICT01
8ms
EVICTION-2: Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=100, Recruiting, ImCheck Therapeutics | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Apr 2024 --> Apr 2025
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
Keytruda (pembrolizumab) • Proleukin (aldesleukin) • ICT01
8ms
On the Safety, Tolerability, and Efficacy of UTAA09 Injection in the Treatment of Lymphoma (clinicaltrials.gov)
P1, N=10, Recruiting, The First Affiliated Hospital with Nanjing Medical University
New P1 trial
9ms
Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT (clinicaltrials.gov)
P1, N=32, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
Trial completion date • Trial primary completion date
9ms
GPC3/Mesothelin-CAR-γδT Cells Against Cancers (clinicaltrials.gov)
P1, N=30, Recruiting, Second Affiliated Hospital of Guangzhou Medical University | Not yet recruiting --> Recruiting | Trial completion date: Dec 2033 --> Dec 2036 | Initiation date: Jan 2024 --> May 2024 | Trial primary completion date: Nov 2026 --> Nov 2030
Enrollment open • Trial completion date • Trial initiation date • Trial primary completion date
9ms
ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML) (clinicaltrials.gov)
P2, N=53, Recruiting, TC Biopharm | N=148 --> 53 | Trial completion date: May 2024 --> Dec 2025 | Trial primary completion date: May 2023 --> Dec 2025
Enrollment change • Trial completion date • Trial primary completion date
|
cyclophosphamide
10ms
New P1 trial
10ms
Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer (clinicaltrials.gov)
P1/2, N=180, Recruiting, Lava Therapeutics | N=66 --> 180 | Trial completion date: Mar 2024 --> Apr 2027 | Trial primary completion date: Sep 2023 --> Apr 2027
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
Keytruda (pembrolizumab)
10ms
New P1 trial • Metastases
|
IL2 (Interleukin 2)
|
Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • ACE2016
11ms
New P1 trial
|
CLN-619
11ms
A Phase 1 Study of ADI-001 in Lupus Nephritis (clinicaltrials.gov)
P1, N=40, Not yet recruiting, Adicet Bio, Inc
New P1 trial
|
cyclophosphamide • fludarabine IV • ADI-001
11ms
ARYA3: T-Cell Therapy (ECT204) in Adults With Advanced HCC (clinicaltrials.gov)
P2, N=30, Recruiting, Eureka Therapeutics Inc. | Trial completion date: Dec 2027 --> Dec 2026
Trial completion date • Metastases
|
GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
cyclophosphamide • Stivarga (regorafenib) • ECT204
11ms
Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases (clinicaltrials.gov)
P=N/A, N=10, Recruiting, PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open
11ms
New trial
11ms
GLEAN-1: A Phase 1 Study of ADI-001 in B Cell Malignancies (clinicaltrials.gov)
P1, N=78, Recruiting, Adicet Bio, Inc | Trial completion date: Mar 2024 --> Dec 2027 | Trial primary completion date: Mar 2023 --> Dec 2025
Trial completion date • Trial primary completion date
|
cyclophosphamide • fludarabine IV • ADI-001
12ms
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) (clinicaltrials.gov)
P1/2, N=6, Terminated, Eureka Therapeutics Inc. | N=12 --> 6 | Trial completion date: Jun 2026 --> Jun 2023 | Recruiting --> Terminated | Trial primary completion date: Apr 2024 --> Jun 2023; Directing efforts to the pediatric study (ARYA-2) for this product
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Metastases
|
AFP (Alpha-fetoprotein)
|
ET140203
12ms
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=410, Recruiting, Cullinan Oncology Inc. | Trial completion date: Mar 2026 --> Jun 2026 | Trial primary completion date: Sep 2025 --> Mar 2026
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase)
|
Keytruda (pembrolizumab) • CLN-619
12ms
ARYA3: T-Cell Therapy (ECT204) in Adults With Advanced HCC (clinicaltrials.gov)
P2, N=24, Recruiting, Eureka Therapeutics Inc. | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2026
Trial completion date • Trial primary completion date • Metastases
|
GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
ECT204
12ms
Directing the migration of serum-free, ex vivo-expanded Vγ9Vδ2 T cells. (PubMed, Front Immunol)
To better understand the migration of these cells and possibly influence their migration, NSG mice were conditioned with agents to clear BM cellular compartments, i.e., busulfan or total body irradiation (TBI), or promote T-cell migration to inflamed BM, i.e., incomplete Freund's adjuvant (IFA), prior to administering γδ T cells...Using an established neuroblastoma NSG mouse model, we show that intratumorally-injected γMSCs increase the homing of γδ T cells to this tumor. These studies provide insight into the migration of serum-free, ex vivo-expanded Vγ9Vδ2 T cells in NSG mice, which is critical to understanding the fundamental properties of these cells.
Preclinical • Journal
|
IFNG (Interferon, gamma) • CCL2 (Chemokine (C-C motif) ligand 2) • CCR2 (C-C Motif Chemokine Receptor 2)
|
IFNG expression
|
busulfan • ET206
1year
Allogenic CD19-targeting CAR-γδT Cell Therapy in r/r NHL (clinicaltrials.gov)
P1/2, N=30, Recruiting, Chinese PLA General Hospital | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
Trial completion date • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6)
|
CD19 positive • Chr t(11;14) • CCND1 overexpression • BCL6 rearrangement • Chr t(11;14)(q13;q32) • BCL2 rearrangement • CD20 negative
|
cyclophosphamide • fludarabine IV
1year
Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC (clinicaltrials.gov)
P1, N=30, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
PSCA (Prostate Stem Cell Antigen 2)
|
cyclophosphamide • fludarabine IV
1year
ARYA3: T-Cell Therapy (ECT204) in Adults With Advanced HCC (clinicaltrials.gov)
P2, N=24, Recruiting, Eureka Therapeutics Inc. | Phase classification: P1/2 --> P2
Phase classification • Metastases
|
GPC3 (Glypican 3)
|
GPC3 expression • GPC3 positive
|
ECT204
1year
Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1) (clinicaltrials.gov)
P1/2, N=12, Recruiting, Eureka Therapeutics Inc. | Phase classification: P2 --> P1/2 | Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jan 2024 --> Apr 2024
Phase classification • Trial completion date • Trial primary completion date • Metastases
|
AFP (Alpha-fetoprotein)
|
ET140203